Fig 2: Recurrence‐free survival (RFS) of 382 patients with invasive breast cancer excluding patients who received neoadjuvant chemotherapy (Cohort 2) according to melanoma‐associated antigen (MAGE)‐A4 expression. Kaplan–Meier curves show the RFS of MAGE‐A4‐negative (blue) and ‐positive (red) patients in Cohort 2.

Fig 3: Recurrence‐free survival (RFS) of patients with triple‐negative breast cancer (TNBC) among 382 patients with invasive breast cancer excluding patients who received neoadjuvant chemotherapy (Cohort 2), according to MAGE‐A4 expression. Kaplan–Meier curves showing the RFS of patients with MAGE‐A4‐negative (blue) and MAGE‐A4‐positive (red) TNBC in Cohort 2.

Fig 4: Overall survival (OS) of patients in 403 patients with invasive breast cancer (Cohort 1) according to MAGE‐A4 expression. The Kaplan–Meier curves show the OS of MAGE‐A4‐negative (blue) and ‐positive (red) patients in Cohort 1.

Fig 5: Validation of the specificity of E701U Ab for MAGE‐A4 expression (HEK293 cells). Each cell block of HEK293 cells, in which MAGE family genes were inserted, was evaluated using E701U (left panels, H&E staining; right panels, E701U Ab).